Zhuhai Trinomab Pharmaceutical Co., Ltd.
Quick facts
Marketed products
Phase 3 pipeline
- HTIG · Oncology
HTIG is a humanized anti-TIGIT monoclonal antibody that blocks the TIGIT immune checkpoint to enhance T-cell mediated anti-tumor immunity. - TNM001 · Oncology
TNM001 is a trispecific antibody that simultaneously engages multiple immune checkpoints to enhance anti-tumor T-cell responses. - TNM002 · Oncology
TNM002 is a monoclonal antibody targeting PD-1.
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: